TOBI tobramycin
Drug Class
Aminoglycoside antibacterial氨基糖苷类抗菌药物
Mechanism
Binds irreversibly to the 30S ribosomal subunit of Pseudomonas aeruginosa, inhibiting bacterial protein synthesis and causing cell membrane disruption and cell death.不可逆地结合铜绿假单胞菌核糖体的30S亚基，抑制细菌蛋白质合成并破坏细胞膜，从而导致细菌死亡。
Approved Indication
Management of cystic fibrosis patients with Pseudomonas aeruginosa.用于治疗伴有铜绿假单胞菌感染的囊性纤维化患者。
What This Means For Patients
TOBI (tobramycin inhalation solution) is an inhaled aminoglycoside antibiotic approved by the FDA. It is delivered directly to the lungs via nebulizer to treat Pseudomonas aeruginosa infections in cystic fibrosis patients, improving pulmonary function. Under special regulatory pathways, patients can access this treatment in the Boao Lecheng pilot zone.TOBI（妥布霉素吸入溶液）是一种获得美国FDA批准的吸入型氨基糖苷类抗生素。它通过雾化吸入直接作用于肺部，用于治疗囊性纤维化患者的铜绿假单胞菌感染，以改善肺功能。符合条件的患者可通过海南博鳌乐城先行区特药通道申请评估使用。
Regulatory Approvals
- FDA — approved (1997) — label
Pivotal Clinical Evidence
- Ramsey et al., 1999 — Ramsey et al., N Engl J Med 1999 — DOI
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.